Evidence map›Paper›PMID 32782480›Full record

ArticleTherapeutic advances in gastroenterology2020

Incidence of

Srishti Saha, Ryan Pardi, Regan N Theiler, Darrell S Pardi, Sahil Khanna

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Antibiotics (Basel, Switzerland) · 2025
    Review
  3. Clinical microbiology reviews · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Srishti SahaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Ryan PardiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Regan N TheilerDepartment of Obstetrics and Gynecology, Division of Obstetrics, Mayo Clinic, Rochester, MN, USA.
Darrell S PardiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Sahil KhannaDivision of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.ORCID https://orcid.org/0000-0002-7619-8338
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of

methodsA single-center retrospective cohort study was conducted in peripartum women from 1997 to 2017. Peripartum CDI was defined as definite CDI (watery diarrhea for >24 h with positive stool assay) during pregnancy, or within 6 weeks postpartum. Incidence was reported per 100,000 pregnancies and time trends in incidence were analyzed using Poisson regression. Analyses were done separately for time trends before and after 2007, when CDI testing strategy changed to polymerase chain reaction.

resultsFrom 1997 to 2017, 80 patients with peripartum CDI (47 during pregnancy, 33 postpartum) out of 125,683 pregnancies (0.064%) were identified. Incidence of CDI increased 3.4 fold (95% confidence interval 1.5-7.4,

conclusionIncidence of CDI in peripartum women increased over the 21 year study period. The rise in incidence is concerning, and calls for heightened surveillance for CDI in this highly vulnerable population.

Indexed as

Clostridioides difficile infectionincidenceobstetricperipartumpregnancy

Identifiers

PMID32782480
PMCPMC7385813
OpenAlexW3045603874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.